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Abstract
Acute kidney injury (AKI) is the most common cause of organ dysfunction in critically ill adults, with a single
episode of AKI, regardless of stage, carrying a significant morbidity and mortality risk. Since the consensus on AKI
nomenclature has been reached, data reflecting outcomes have become more apparent allowing investigation of
both short- and long-term outcomes.
Classically the short-term effects of AKI can be thought of as those reflecting an acute deterioration in renal
function per se. However, the effects of AKI, especially with regard to distant organ function (“organ cross-talk”), are
being elucidated as is the increased susceptibility to other conditions. With regards to the long-term effects, the
consideration that outcome is a simple binary endpoint of dialysis or not, or survival or not, is overly simplistic, with
the reality being much more complex.
Also discussed are currently available treatment strategies to mitigate these adverse effects, as they have the
potential to improve patient outcome and provide considerable economic health savings. Moving forward, an
agreement for defining renal recovery is warranted if we are to assess and extrapolate the efficacy of novel
therapies. Future research should focus on targeted therapies assessed by measure of long-term outcomes.
Background
Acute kidney injury (AKI) is the most common cause
of organ dysfunction in critically ill adults with an
incidence of around 34 %, and carries an observed in-
hospital mortality as high as 62 % [1]. Indeed, even a
single episode of AKI carries a significant morbidity
and mortality risk, with an episode of stage 1 AKI
complicating a critical illness being independently as-
sociated with an increase in 10-year mortality [2].
Moreover, the long-term effects of AKI also contrib-
ute significantly to health costs and, in the UK, has
been estimated to account for about 1 % of the total
health and social care budget.
In this narrative review we will consider how, since a
consensus has been reached, the effects of kidney injury
on both short- and long-term outcomes have been
highlighted.
Defining renal injury
Table 1 describes the terminology used to describe
and define AKI throughout its course from that
described by the Kidney Disease Improving Global
Outcomes (KDIGO) and others [3, 4].
The definition of chronic kidney disease (CKD) as
published by the KDIGO guidelines is outlined in
Table 1, with the latest review including ‘with implica-
tions for health’ in an attempt to contextualize the no-
tion that a variety of kidney functional anomalies may
exist that will not have bearing on the patient’s health
long term. CKD has then been sub-classified based on
cause, estimated glomerular filtration rate (eGFR), or al-
buminuria category into stages 1–5 [3].
Perhaps the most challenging area to define is that of
renal recovery; however, this is of vital importance, as a
consensus agreement would likely yield a framework for
efficacy of assessment of novel emerging therapies. How-
ever, it is not without difficulty. Within the critical care
arena some would consider renal recovery as the return
of eGFR to pre-morbid baseline levels (whatever that
means in the context of critical illness) whilst others
may consider the absence of the need for renal replace-
ment therapy (RRT) as sufficient recovery. Studies
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reporting renal recovery are often ambiguous at best.
There has been some attempt at the classification of
renal recovery [5] (Table 2).
However, using a crude marker of renal function such
as serum creatinine outside steady-state conditions has
significant limitations. Serum creatinine is used as a sur-
rogate for the glomerular filtration rate (GFR) during
AKI in critically ill unstable patients. The GFR is rarely
measured in clinical practice but equations, such as the
modification of diet in renal disease (MDRD) and
the chronic kidney disease epidemiology collabor-
ation (CKD-EPI) equations, estimate the GFR (eGFR)
from the serum creatinine where differences in age,
sex, and race are considered [6–8]. However, as
noted, creatinine is a biomarker for the GFR only
under clinically stable conditions [9]. In the critically
ill there is a significant overestimation of the eGFR
due to, for example, reduced creatinine levels due to
reduced muscle bulk and creatinine generation. Sev-
eral studies have compared formal measurement of
the GFR and eGFR with considerable disparity ob-
served [10]. Most importantly, of course, is that
there is a delay between renal injury and any ob-
served rise in creatinine, which may be masked for
up to 48 h.
Risk prediction
In terms of outcomes from AKI, various factors may in-
fluence both short- and long-term sequelae (Fig. 1). For
example, the presence of pre-existing CKD has a
significant impact on long-term outcomes. One retro-
spective study demonstrates that CKD not only predis-
poses an individual to a higher risk of AKI but also
longer duration of RRT, and more in-hospital resuscita-
tion was observed in this group. Indeed, eGFR was an
independent predictor of both 30-day mortality (hazard
ratio (HR) 0.994, 95 % confidence interval (CI) 0.990–
0.998) and 1-year mortality (HR 0.996, 95 % CI
0.993–1.000) [11]. Unsurprisingly, other risk factors
for the development of AKI, such as age and diabetes,
are also associated with worse outcomes. In patients
with AKI aged over 65 years when matched to a
younger cohort worse outcomes were found at
3 months, although the longer term outcome was in-
dependent of age [12]. Clearly, the severity of any
concomitant illness will also play a considerable role
in outcome and ultimately decide prognosis despite
the improvement in supportive organ support for crit-
ically unwell patients [13]. Similarly, the increasing
complexity of procedures offered to patients with sig-
nificant comorbidities is increasing with a rise in AKI.
Patients undergoing coronary artery bypass grafting
have a risk of AKI in one series of 2.5 % compared
to 4.6 % of patients undergoing valvular surgery [14].
Exposure to nephrotoxins, including contrast, also
plays a role in determining outcome; contrast
administration is associated with increased need for
RRT, worse renal function at discharge, and longer
length of stay, as well as worse short-term mortality
[15]. Furthermore, the choice of resuscitation fluid
employed can also have significant consequences as is
the case for some hydroxyethyl starch (HES) derivatives,
where increased need for RRT and increased mortality in
patients that were resuscitated with HES has been ob-
served [16, 17]. Risk assessment may be enhanced by the
use of scoring systems such as the Sequential Organ
Failure Assessment (SOFA) and the Acute Physiology and
Chronic Health Evaluation (APACHE), of which there are
Table 1 Defining renal injury
Renal Injury Description
Acute kidney injury (AKI) Defined according to changes in
serum creatinine and urine output,
and described as stages 1, 2 and 3
Recurrent kidney injury (RKI) An episode of repeated renal injury
following recovery of the index case
Acute kidney disease (AKD) Describes the transition between
the acute and chronic states (day 7
post-AKI to day 90)
Chronic kidney disease (CKD) Abnormalities of kidney structure
or function for >3 months, with
implications for health
Table 2 Potential definition of renal recovery
Renal recovery Assessment
Complete Return of pre-AKI renal function, assessed as
eGFR ±10 % of baseline
Partial Persistent impaired eGFR, but no requirement
for RRT
Absent Persistent requirement for RRT
Data adapted from Schiffl and Fischer [5]. AKI acute kidney injury, eGFR
estimated glomerular filtration rate, RRT renal replacement therapy
Fig. 1 Influences on outcome for AKI. Influences of various
co-morbidities on the development of AKI, and unfavourable
long-term outcomes. AKI acute kidney injury, CKD chronic
kidney disease, DM diabetes mellitus
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several variations. For example, the occurrence of a con-
current AKI and SOFA score >11 confers a significant
negative short-term outcome [1]. There are considerable
data on the development of AKI, particularly in the surgi-
cal patient; however, no system is uniquely placed in terms
of predictive ability. Consequently, much effort has been
focused on the development of ‘biomarkers’ for AKI in
order to enhance early detection [18]. Many studies have
utilized biomarkers alone or in combination with
scoring systems and, recently, combination biomarkers
of cell cycle arrest: tissue inhibitor of metalloprotein-
ases (TIMP)-2/insulin-like growth factor binding pro-
tein (IGFBP)-7, together with urine output and serum
creatinine, has been validated to be superior to pre-
dicting dialysis requirements at 9 months in patients
with AKI compared to creatinine alone [19–22].
Interestingly, some biomarkers have been observed to
remain elevated years after an episode of AKI, al-
though it is unclear whether this translates into
continuous pathological insult. This is an obstacle in
considering novel methods employing biomarkers in
terms of defining renal recovery.
Short-term effects of AKI
Classically, the short-term effects of AKI can be thought
of as those reflecting an acute deterioration in renal
function per se, and include disturbances in acid-base
and electrolyte homeostasis, uraemia and the conse-
quences thereof, as well as volume overload through salt
and water retention complicating AKI in many patients.
This is outlined in Fig. 2. Increasingly, the effects of
AKI, especially with regard to distant organ function (so
called “organ cross-talk”), is being elucidated as is the
increased susceptibility to other conditions, although it
can be difficult to determine the exact relationship be-
tween cause and effect. An example of this is sepsis,
where the presence of AKI, through effects on the innate
immune system, predisposes to an episode of sepsis; this
may in turn exacerbate the severity of AKI.
AKI is often associated with volume overload and this
seems to be a major contributing factor to both morbid-
ity and mortality. Indeed, a retrospective analysis of
post-operative percentage fluid overload (PFO) in pa-
tients at AKI stage 3 after cardiac surgery illustrated this
with a PFO >7.2 % throughout the intensive care unit
(ICU) stay being significantly associated with reduced
90-day survival (P < 0.001) [23]. As a consequence, insti-
gation of RRT, at least in the ICU setting, is often trig-
gered by oliguria and volume overload despite a paucity
of data supporting this approach. Further support for
this approach comes from a prospective multi-centre ob-
servational study in patients with AKI where a positive
fluid balance at initiation of RRT of >3 L/24 h (odds ra-
tio (OR) 2.3, 95 % CI 1.2–4.5) and PFO >5 % (OR 2.3,
95 % CI 1.2–4.7) was associated with higher mortality
[24]. Therefore, it would appear that limiting volume
overload is associated with improved outcomes, and that
early initiation of RRT may confer a survival benefit. To
date there is no evidence from randomised controlled
studies that such an approach, albeit attractive, is advan-
tageous. Also, early instigation of treatment must be bal-
anced against the risks associated with commencing
such an invasive technique.
AKI: a systemic disease?
As pointed out, as well as the conventional clinical fea-
tures associated with AKI there is also increasing evi-
dence that this syndrome is associated with an increased
risk of developing further complications. The PICARD
study, an observational multi-centre study of 618 critic-
ally ill patients showed that 40 % went on to develop
sepsis after AKI had occurred. Compared to those with-
out sepsis but with AKI, there was an increase in length
of stay (LOS; 37 vs 27 days; P < 0.001), risk of dialysis re-
quirement (70 vs 50 %; P < 0.001) and mortality (44 vs.
21 %; P < 0.0001) [25]. Such observations have led to a
considerable body of evidence, principally from animal
and laboratory work, highlighting the effect of AKI on
the immune system. Various mechanisms have been pro-
posed to explain this phenomenon including reduced
pro-inflammatory cytokine clearance [26] and impaired
neutrophil function [27]. It follows that such sequelae
will have consequences over and above that of changes
in urine output and serum creatinine, and, as such, AKI
is associated with multi-system effects. This systemic ap-
proach to AKI is reflected in other short-term effects.
An episode of AKI confers an increased risk of further
episodes of AKI, perhaps through the mechanisms de-
scribed, the subsequent development of acute kidney
disease (AKD), and ultimately the risk of CKD. In some
studies, recurrent kidney injury was seen in up to 31 %
of patients who had higher hospital and 1-year mortality
[28]. LOS and hospital re-admission are also associated
with the development of AKI. Studies from the UK
demonstrate that LOS has been reported as 1.5-, 1.9-,
and 2.2-fold greater in those with Acute Kidney Injury
Network (AKIN) 1, AKIN 2, and AKIN 3 [29]. More-
over, the same study reported an increase in hospital re-
admission rate, with an increased 30-day re-admission
(OR 1.93, 95 % CI 1.75–2.13) irrespective of severity of
AKI [29]. The major short-term effect of AKI is, of
course, mortality. An increase in hospital, ICU, 30- and
90-day mortality following AKI has been repeatedly
shown, and the mortality effects of this clinical syndrome
are now generally accepted. In a large UK retrospective
observational database study extrapolated to an entire
hospital setting of over 36,000 admissions, in-hospital
mortality was recorded as non-AKI 2.0 %, AKI-1 8.1 %,
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AKI-2 25.6 %, and AKI-3 33.3 % [29]. Another retrospect-
ive cohort study on severity of AKI (not requiring dialysis)
with a 90-day follow-up showing progression to stage 3, 4,
and 5 CKD increased the risk of mortality by 0.7 %,
2.3 %, and 4.1 %, respectively [7]. This observation is
consistent across different patient groups. For example,
in critically unwell trauma patients, the rate of 30-day
mortality was 17.5 % in an AKI cohort versus 5.8 % in
the non-AKI cohort in a large observational trial in
Sweden [30].
Long-term effects of AKI
Until fairly recently, follow-up studies of survivors of
critical care have focused, primarily, on short-term out-
comes, such as 28-day mortality or length of hospital
stay. This is of particular relevance when one considers
the effects of AKI. Rather than the outcome being a sim-
ple binary endpoint of dialysis or not, or survival or not,
the picture is much more complex and worrying than
that. If one considers some of the economic burden of
the treatment of AKI, for example, this is considerable.
Indeed, observational studies demonstrate a significant
deterioration of renal function in patients that have
survived an episode of AKI with an apparent initial
resolution, measured as eGFR. Follow-up from a
retrospective observational cohort in 2012 showed
progression of renal impairment by 90 days post-
index AKI [7]. Furthermore, a prospective observa-
tion study of a cohort of 226 survivors of AKI
patients treated with RRT found that 14 % had CKD
at the end of the 5-year follow-up period [5] The
long-term effects on renal function are common
even where “renal recovery”, as determined by return
of eGFR to pre-morbid levels, has occurred. Persist-
ent microalbuminuria for periods as long as 4 years
post-AKI have been observed [31]. The effect of an
episode of AKI was elegantly demonstrated by
Kolonko et al., who observed that the long-term risk
for graft loss was significantly higher among the
group of kidneys recovered from donors with AKI
than those without (27.8 % vs 7.1 %; P = 0.02) [32].
Interestingly, the need for long-term dialysis is also
related to AKI. The RENAL study follow-up demon-
strated 5.4 % long-term requirement for maintenance
dialysis after an episode of AKI requiring RRT, with
Schiffl and Fischer reporting a similar incidence of
Fig. 2 Classical short-term effects of AKI. Short-term effects have always been considered those that occur as a consequence of the acute
deterioration in renal function. AKI acute kidney injury
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5 % [5, 31]. A pooled analysis by Goldberg and Dennen
found a wide range of results, depending on patient popu-
lation, but an average long-term dialysis requirement of
12.5 % in survivors over follow-up periods of 1 to 10 years
[33]. In keeping with a long-term risk for chronic RRT, pa-
tients surviving AKI also have an increased rate of both
adverse cardiovascular and cerebrovascular events. In a
large, matched cohort of over 4000 patients, the incidence
of coronary events were 19.8 and 10.3 per 1000 person
years in the AKI and the non-AKI group, respectively (HR
1.67, 95 % CI 1.36–2.04), and the incidence of stroke was
both higher (HR 1.25; P = 0.037) and of increased severity
in the AKI group [34]. Following on from these observa-
tions, it would seem likely that quality of life (QOL) indi-
ces also show a relationship with AKI. A prospective,
matched cohort study compared long-term outcome and
QOL in patients with AKI requiring RRT compared to
matched controls using the EuroQOL-SD and Short-Form
(SF)-36 before ICU admission, then at 3 months, 1 year
and 4 years after ICU discharge. Surprisingly, despite a
higher severity of illness and 28.6 % remaining dialysis-
dependent in the AKI-RRT group, the QOL scores were
comparable to non-AKI RRT patients. Interestingly, both
groups had worse QOL scores than the general public. As
expected, the lowest QOL level was at 3 months and then
improved, although still below baseline, at 1 and 4 years
[35]. These results were mirrored by data from the
FINNAKI study, with non-significant differences in
EuroQOL-SD measurement at 6 months between AKI
and non-AKI ICU patients [36]. However, despite
these observations, it is known that in the USA an
episode of AKI confers an OR of 2 for the require-
ment of transfer from hospital to a long-term care fa-
cility [37].
As discussed, an episode of AKI carries a significant
short-term mortality risk depending on the severity of
AKI, and this relationship also holds for longer term
outcomes. In an extended follow up of the RENAL
study, there were 810 survivors form the original
RENAL study at day 90, of which 32 % died during the
4-year follow-up period, reflecting an overall mortality
rate of 62 % in the study cohort [31]. In keeping with
these results, the FINNAKI study reported 6-month
mortality at 35.5 % for AKI patients and 16.5 % for non-
AKI patients admitted with a critical illness [36]. A re-
cent prospective cohort evaluation of 2010 ICU patients
in a tertiary centre revealed an adjusted 10-year mortal-
ity risk of 1.26 (1.0–1.6). After propensity matching,
even stage 1 AKI was associated with decreased 10-year
survival (P = 0.036) [2].
These long-term outcomes for AKI repeatedly demon-
strate high mortality rates; for example, Morgera and
Hans, in 979 RRT-requiring AKI patients: 14 % 5-year
survival [13]. Interestingly, careful analysis of mortality
outcome has revealed a biphasic pattern [38]: an initial
high rate of mortality in the immediate post-AKI setting
followed by a steady, but increased, mortality rate against
matched non-AKI controls.
It must be remembered that AKI is not a clinical diag-
nosis but a clinical syndrome characterized by a cluster
of observations. The causes of AKI are numerous, and
therefore it comes as no surprise that the varying aeti-
ology of AKI may also affect long-term outcome. This is
seen in a single-centre analysis of mortality after AKI at
6 months and 5 years. Only a small increase in mortality
from 6 months to 5 years was seen (10 %), potentially
explained by a higher than usual contribution due to in-
toxication and rhabdomyolysis. Regardless, the total all-
cause 5-year mortality was high at 65 % and consistent
with other long-term outcome AKI studies [39]. Finally
of note is the fact that the development of advanced
CKD, dialysis dependence, and mortality are competitive
endpoints, as many patients surviving AKI do not live
long enough to develop advanced CKD requiring dialy-
sis, for example.
Treatment options to limit the effects of AKI
The development of unique treatments during an epi-
sode of AKI to mitigate the observed short- and
long-term effects have not met with success. It is
likely that a combination of therapeutic strategies will
result in the best outcome given the multifactorial na-
ture of AKI. The components of these strategies are
now being recognized and may include rapid detec-
tion and management as well as choice of treatment,
which may well impact on both short- and long-term
outcomes. Such a relationship is reflected in the
mode of RRT used during AKI, which has been
shown to affect long-term outcome. A retrospective
cohort study in Canada of over 4000 propensity-
matched patients undergoing intermittent dialysis
compared to those on continuous renal replacement
therapy (CRRT) showed that the risk of long-term
dialysis-dependence was significantly reduced in the
group of patients that initially received CRRT (HR
0.75, 95 % CI 0.65–0.87). This result was even more
significant in those with pre-existing CKD or heart
failure [40]. Interestingly, these results are not con-
sistent with the recently released 4-year extended
follow-up of the RENAL study in which there was no
benefit of higher dose RRT in terms of mortality or
long-term dialysis-dependence [31]. However, there
appears to be clear benefit with the use of CRRT
compared to intermittent RRT (IRRT) as an inde-
pendent predictor of renal recovery [41]. Although
there may be a survival benefit where CRRT is used,
there is little evidence that the timing of RRT has
any effects on outcome. A recent retrospective review
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from China demonstrated no difference in outcome
with early versus late RRT [42].
Perhaps the most important consideration in terms of
long-term follow-up is that treatment should remain in-
line with the management of CKD.
As such, mitigation of long-term effects should include:
1. Referral to a nephrology specialist, with evidence
demonstrating a reduced all-cause mortality in
patients with severe AKI who undergo RRT. In
addition, early referral in patients with CKD also
demonstrates a survival benefit [43, 44].
2. Control of hypertension with manipulation of the
renin-angiotensin-aldosterone system.
3. Heavy proteinuric states should have more aggressive
control of hypertension and use of anti-proteinuric
agents.
4. Consideration of the high-risk nature of developing
AKI in those with CKD during critical illness.
5. General cardiovascular health, lifestyle, and dietary
advice.
Conclusion
The finding that critically unwell patients with AKI who
survive the index case continue to have increased mor-
bidity and mortality long-term remains unexplained, but
is significant. Future research should focus on these pa-
tients with targeted therapies assessed by measure of
long-term outcomes.
A consensus agreement for defining renal recovery
is warranted if we are to assess and extrapolate the
efficacy of novel therapies. Currently available treat-
ment strategies have the potential to improve patient
outcome and provide considerable economic health
savings provided they are adopted early in the course
of the patient’s illness with appropriate specialist
follow-up to be recommended.
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